Gas Accretion via Lyman Limit Systems

In cosmological simulations, a large fraction of the partial Lyman limit systems (pLLSs; 16<log N(HI)<17.2) and LLSs (17.2log N(HI)<19) probes large-scale flows in and out of galaxies through their circumgalactic medium (CGM). The overall low metallicity of the cold gaseous streams feeding galaxies seen in these simulations is the key to differentiating them from metal rich gas that is either outflowing or being recycled. In recent years, several groups have empirically determined an entirely new wealth of information on the pLLSs and LLSs over a wide range of redshifts. A major focus of the recent research has been to empirically determine the metallicity distribution of the gas probed by pLLSs and LLSs in sizable and representative samples at both low (z2) redshifts. Here I discuss unambiguous evidence for metal-poor gas at all z probed by the pLLSs and LLSs. At z<1, all the pLLSs and LLSs so far studied are located in the CGM of galaxies with projected distances <100-200 kpc. Regardless of the exact origin of the low-metallicity pLLSs/LLSs, there is a significant mass of cool, dense, low-metallicity gas in the CGM that may be available as fuel for continuing star formation in galaxies over cosmic time. As such, the metal-poor pLLSs and LLSs are currently among the best observational evidence of cold, metal-poor gas accretion onto galaxies.Comment: Invited review to appear in Gas Accretion onto Galaxies, Astrophysics and Space Science Library, eds. A. J. Fox & R. Dav\'e, to be published by Springe

Gas Accretion in Star-Forming Galaxies

Cold-mode gas accretion onto galaxies is a direct prediction of LCDM simulations and provides galaxies with fuel that allows them to continue to form stars over the lifetime of the Universe. Given its dramatic influence on a galaxy's gas reservoir, gas accretion has to be largely responsible for how galaxies form and evolve. Therefore, given the importance of gas accretion, it is necessary to observe and quantify how these gas flows affect galaxy evolution. However, observational data have yet to conclusively show that gas accretion ubiquitously occurs at any epoch. Directly detecting gas accretion is a challenging endeavor and we now have obtained a significant amount of observational evidence to support it. This chapter reviews the current observational evidence of gas accretion onto star-forming galaxies.Comment: Invited review to appear in Gas Accretion onto Galaxies, Astrophysics and Space Science Library, eds. A. J. Fox & R. Dav\'e, to be published by Springer. This chapter includes 22 pages with 7 Figure

Emission from the circumgalactic medium: from cosmological zoom-in simulations to multiwavelength observables

We simulate the flux emitted from galaxy haloes in order to quantify the brightness of the circumgalactic medium (CGM). We use dedicated zoom-in cosmological simulations with the hydrodynamical adaptive mesh refinement code ramses, which are evolved down to z = 0 and reach a maximum spatial resolution of 380 h−1 pc and a gas mass resolution up to 1.8×105h−1M⊙ in the densest regions. We compute the expected emission from the gas in the CGM using cloudy emissivity models for different lines (e.g. Lyα, C iv, O vi, C vi, O viii) considering UV background fluorescence, gravitational cooling and continuum emission. In the case of Lyα, we additionally consider the scattering of continuum photons. We compare our predictions to current observations and find them to be in good agreement at any redshift after adjusting the Lyα escape fraction. We combine our mock observations with instrument models for Faint Intergalactic Redshifted Emission Balloon-2 (FIREBall-2; UV balloon spectrograph) and HARMONI (visible and NIR IFU on the ELT) to predict CGM observations with either instrument and optimize target selections and observing strategies. Our results show that Lyα emission from the CGM at a redshift of 0.7 will be observable with FIREBall-2 for bright galaxies (NUV∼18 mag), while metal lines like O vi and C iv will remain challenging to detect. HARMONI is found to be well suited to study the CGM at different redshifts with various tracers

Emission from the circumgalactic medium: from cosmological zoom-in simulations to multiwavelength observables

We simulate the flux emitted from galaxy haloes in order to quantify the brightness of the circumgalactic medium (CGM). We use dedicated zoom-in cosmological simulations with the hydrodynamical adaptive mesh refinement code RAMSES, which are evolved down to z = 0 and reach a maximum spatial resolution of 380 h−1 pc and a gas mass resolution up to 1.8×105 h−1 M⊙ in the densest regions. We compute the expected emission from the gas in the CGM using CLOUDY emissivity models for different lines (e.g. Lyα, C IV, O VI, C VI, O VIII) considering UV background fluorescence, gravitational cooling and continuum emission. In the case of Lyα, we additionally consider the scattering of continuum photons. We compare our predictions to current observations and find them to be in good agreement at any redshift after adjusting the Lyα escape fraction. We combine our mock observations with instrument models for Faint Intergalactic Redshifted Emission Balloon-2 (FIREBall-2; UV balloon spectrograph) and HARMONI (visible and NIR IFU on the ELT) to predict CGM observations with either instrument and optimize target selections and observing strategies. Our results show that Lyα emission from the CGM at a redshift of 0.7 will be observable with FIREBall-2 for bright galaxies (NUV∼18 mag), while metal lines like O VI and C IV will remain challenging to detect. HARMONI is found to be well suited to study the CGM at different redshifts with various tracers.</p

Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

Aims to compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and Results 15 078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg-1 as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. (C) 2000 The European Society of Cardiology

The European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease

Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4·2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% β blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% Cl 9–29, p=0·0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease